Western Institutional Review Board Receives ISO 9001:2008 Certification
PRINCETON, N.J., Mar. 16, 2015 – WIRB-Copernicus Group (WCG), the world’s largest provider of regulatory and ethical review services and software to support clinical research, announced today that its Western Institutional Review Board® (WIRB®) company has been certified to ISO 9001:2008 by BSI, confirming that it operates an excellent quality management system.
“WIRB and its sister IRB, Copernicus Group, are the only two IRBs to have met ISO quality management standards and to have received ISO 9001:2008 certification,” commented WCG Chairman and CEO Donald A. Deieso, Ph.D. “We are proud to have set a new high bar for quality management in ethical review.”
“At WCG, we are always looking for ways to increase efficiencies within the clinical research process while – most importantly – maintaining the highest standards of human subject protection,” added WCG Chief Compliance Officer David Forster, JD, MA, CIP. “Achieving ISO certification is a powerful indicator of our commitment to continuous improvement in all aspects of our operations.”
Todd VanderVen, president of BSI Americas, stated, “WIRB is to be congratulated for its achievement of certification to ISO 9001:2008. Given Copernicus Group IRB’s earlier certification, WIRB’s achievement sends a clear message of WCG’s commitment to quality and dedication to continual improvement.”
All ISO 9000 standards are based on a series of quality management principles. They require company leaders to establish clear goals and objectives for their quality management system and endeavor to get all their employees involved. Participating companies adopt a strong customer focus with employees aiming not just to meet customer expectations but to exceed them. They also take both a process- and systems-based management approach, and strive for continual improvement in their company’s overall performance, using internal audits to track progress.
ISO 9001:2008 is implemented by more than one million companies and organizations in more than 170 countries, according to ISO.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
